FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1764756972> ?p ?o ?g. }

• W1764756972 endingPage "9020" @default.
• W1764756972 startingPage "9020" @default.
• W1764756972 abstract "9020 Background: Olanzapine (OLN) has been shown to be a safe and effective agent for the prevention of CINV. In combination with other antiemetics, aprepitant (APR) has been approved for the prevention of acute and delayed CINV in patients receiving highly emetogenic chemotherapy (HEC). Methods: A phase III trial was performed for the prevention of CINV in chemotherapy naïve patients receiving HEC (cisplatin, ≥70 mg/m2 or doxorubicin, ≥50 mg/m2) comparing OLN to APR in combination with palonosetron (PALO) and dexamethasone (DEX). The OLN regimen was 10 mg of oral OLN, 0.25 mg of intravenous (IV) PALO, and DEX 20 mg IV on the day of chemotherapy, day 1, and 10 mg/day of oral OLN alone on days 2-4 after chemotherapy. The APR regimen was 125 mg of oral APR, 0.25 mg IV PALO, and 12 mg IV DEX, day 1, and 80 mg oral APR, 4 mg DEX BID, days 2-3. Fifty patients (median age 58 yrs, range 39-81; 29 females; ECOG PS 0,1) consented to the protocol and all were evaluable. Results: Complete response (CR) (no emesis, no rescue) was 100% for the acute period (24 h post-chemotherapy), 75% for the delayed period (days 2-5 post-chemotherapy), and 75% for the overall period (0-120 h) for 27 patients receiving the OLN regimen. CR was 87% for the acute period, 70% for the delayed period, and 70% for the overall period in 23 patients receiving the APR regimen. Patients without nausea (0, scale 0-10, M.D. Anderson Symptom Inventory) was: OLN: 88%, acute; 65%, delayed; and 65%, overall; APR: 88%, acute; 38%, delayed; and 38% overall. There were no Grade 3 or 4 toxicities. CR and control of nausea in subsequent cycles of chemotherapy (45 patients, cycle 2; 41 patients cycle 3; 33 patients, cycle 4) were equal to or greater than cycle one for both regimens. Conclusions: OLN was comparable to APR in the control of CINV in patients receiving HEC. Nausea was better controlled with OLN. No significant financial relationships to disclose." @default.
• W1764756972 created "2016-06-24" @default.
• W1764756972 creator A5010949205 @default.
• W1764756972 creator A5059899831 @default.
• W1764756972 creator A5076594436 @default.
• W1764756972 date "2010-05-20" @default.
• W1764756972 modified "2023-09-24" @default.
• W1764756972 title "Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV): A randomized phase III trial." @default.
• W1764756972 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.9020" @default.
• W1764756972 hasPublicationYear "2010" @default.
• W1764756972 type Work @default.
• W1764756972 sameAs 1764756972 @default.
• W1764756972 citedByCount "8" @default.
• W1764756972 countsByYear W17647569722013 @default.
• W1764756972 countsByYear W17647569722014 @default.
• W1764756972 countsByYear W17647569722015 @default.
• W1764756972 countsByYear W17647569722016 @default.
• W1764756972 countsByYear W17647569722018 @default.
• W1764756972 crossrefType "journal-article" @default.
• W1764756972 hasAuthorship W1764756972A5010949205 @default.
• W1764756972 hasAuthorship W1764756972A5059899831 @default.
• W1764756972 hasAuthorship W1764756972A5076594436 @default.
• W1764756972 hasConcept C126322002 @default.
• W1764756972 hasConcept C2776694085 @default.
• W1764756972 hasConcept C2776712918 @default.
• W1764756972 hasConcept C2779924295 @default.
• W1764756972 hasConcept C2780574406 @default.
• W1764756972 hasConcept C2780580376 @default.
• W1764756972 hasConcept C2780852908 @default.
• W1764756972 hasConcept C2780884295 @default.
• W1764756972 hasConcept C2781413609 @default.
• W1764756972 hasConcept C42219234 @default.
• W1764756972 hasConcept C71924100 @default.
• W1764756972 hasConceptScore W1764756972C126322002 @default.
• W1764756972 hasConceptScore W1764756972C2776694085 @default.
• W1764756972 hasConceptScore W1764756972C2776712918 @default.
• W1764756972 hasConceptScore W1764756972C2779924295 @default.
• W1764756972 hasConceptScore W1764756972C2780574406 @default.
• W1764756972 hasConceptScore W1764756972C2780580376 @default.
• W1764756972 hasConceptScore W1764756972C2780852908 @default.
• W1764756972 hasConceptScore W1764756972C2780884295 @default.
• W1764756972 hasConceptScore W1764756972C2781413609 @default.
• W1764756972 hasConceptScore W1764756972C42219234 @default.
• W1764756972 hasConceptScore W1764756972C71924100 @default.
• W1764756972 hasIssue "15_suppl" @default.
• W1764756972 hasLocation W17647569721 @default.
• W1764756972 hasOpenAccess W1764756972 @default.
• W1764756972 hasPrimaryLocation W17647569721 @default.
• W1764756972 hasRelatedWork W100286279 @default.
• W1764756972 hasRelatedWork W1480067006 @default.
• W1764756972 hasRelatedWork W160231609 @default.
• W1764756972 hasRelatedWork W2032692004 @default.
• W1764756972 hasRelatedWork W2052445101 @default.
• W1764756972 hasRelatedWork W2057039455 @default.
• W1764756972 hasRelatedWork W2155434997 @default.
• W1764756972 hasRelatedWork W22360130 @default.
• W1764756972 hasRelatedWork W2806893525 @default.
• W1764756972 hasRelatedWork W3096722963 @default.
• W1764756972 hasVolume "28" @default.
• W1764756972 isParatext "false" @default.
• W1764756972 isRetracted "false" @default.
• W1764756972 magId "1764756972" @default.
• W1764756972 workType "article" @default.